Acute effects of human recombinant erythropoietin on cardiovascular dynamics and vasoactive substances

Japanese Journal of Nephrology

Volumn 38, Issue 12, 1996, Pages 634-639

  Suga, Masaru ^a   Kurihara, Satoshi ^b   Iino, Yasuhiko ^a   Terashi, Akiro ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b Kasukabe Shuwa Hospital   (Japan)

Author keywords

Cardiovascular dynamics; Chronic renal failure; Hypertension; Recombinant human erythropoietin; Vasoactive substances

Indexed keywords

ANGIOTENSIN; RECOMBINANT ERYTHROPOIETIN; VASOACTIVE AGENT;

ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; HEMODYNAMICS; HUMAN; HYPERTENSION; INTRAARTERIAL DRUG ADMINISTRATION; LUNG VASCULAR RESISTANCE; VASOCONSTRICTION;

ANGIOTENSIN II; DOPAMINE; ENDOTHELINS; EPINEPHRINE; ERYTHROPOIETIN; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; RECOMBINANT PROTEINS;

EID: 0030476388     PISSN: 03852385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Bommer J, Alexiou C, Muller-Buhl U, Eifert J, Ritz E: Recombinant human erythropoietin therapy in haemodialysis patients dose determination and clinical experience. Nephr Dial Transplant 2: 238-242, 1987
2. Esbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, Korbet S, Krantz SB, Lundin AP, Nissenson AR, Ogden DA, Paganini EP, Rader B, Rutsky EA, Stivelman J, Stone WJ, Teschan P, Van Stone JC, Van Wyck DB, Zuckerman K, Adamson JW: Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of phase III multicenter clinical trial. Ann Int Med 111: 992-1000, 1989
3. Samtleben W, Baldamus CA, Bommer J, Fassbinder W, Nonnast DB, Gurland HJ: Blood pressure changes during treatment with recombinant human erythropoietin. Contr Nephrol 66: 114-122, 1988
4. Bode Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC: Endothelin release and shift in prostaglandin balance are involved in the modulation of vascular tone by recombinant erythropoietin. J Cardiovasc Pharmacol 20: S 25-28, 1992
5. Carlini RG, Dusso AS, Obialo CI, Alvarez UM, Rothstein M: Recombinant human erythropoietin (rHuEPO) increases endothelin - 1 release by endothelial cells. Kidney Int 43: 1010-1014, 1993
6. Neff MS, Kimm KE, Persoff M, Onesti G, Swartz C: Hcmodynamics of uremie anemia. Circulation 43: 876-883, 1971
7. Akiba T, Kurihara S, Katoh H, Yoneshima H, Marumo F: Hemodainamic change of hemodialyzed patients by erythropoietin (Ep) treatment. Kidney Int 35: 237, 1989
8. Pascual J, Teruel JL, Marcen R, Liano F, Ortuno J: Blood pressure after three different forms of correction of anemia in hemodialysis. Int J Artif Organs 15: 393-396, 1992
9. Carlini R, Obialo CI, Rothstein M: Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertens 6 : 103-107, 1993
10. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M: Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 87: 5978-5982, 1990
11. Heidenreich S, Rahn KH, Zidek W: Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 39: 259-265, 1991
12. Takayama K, Nagai T, Kinugasa E, Akizawa T, Koshikawa S: Changes in endothelial vasoactive substances under recombinant human erythropoietin therapy in hemodialysis patients. ASAIO Trans. 37: M 187 -188, 1991
13. Buemi M, Morabito N, Palella S, Allegra A, Frisina N, Gemetli M, Manganaro R, Stelitano L, Palmara A: Influence of recombinant erythropoietin on the production of endothelin-1 from human umbilical artery. Nephron 64: 165-166, 1993
14. Takahashi K, Totsune K, Imai Y, Sone M, Nozuki M, Murakami O, Sekino H, Mouri T: Plasma concentration of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erithropoietin. Clin Scie 84: 47-50, 1993
15. Katoh K, Mizuno K, Hashimoto S, Okazaki K, Asahi K, Kuriki M, Yamada D, Fukuchi S: Direct evidence for erythropoietin-induced release of endothelin from peripheral vascular tissue. Life Sci 54: PL 253-259, 1994
16. Muntzel M, Hannedouche T, Lacour B, Drueke T: Effect of erythropoietin on hematocrit and blood pressure in normotensive and hypertensive rats. J Am Soc Nephrol 3 : 182-187, 1992
17. Nonnast DB, Deschodt G, Brunkhorst R, Creutzig A, Bahlmann J, Shaldon S, Koch KM: Long term effects of treatment with recombinant human erythropoietin on hemodynamics and tissue oxygenation in patients with renal anemia. Nephrol Dial Transplant 5 : 444-448, 1990